ArticleCureus2025
C-reactive Protein/Albumin Ratio as a Prognostic Indicator for Predicting Surgical Intervention in Neonates With Necrotizing Enterocolitis: A Prospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Surgical Necrotising Enterocolitis (S-NEC): Where We Stand Today: A Narrative Review.Journal of clinical medicine · 2026Review
- C-reactive protein-to-albumin ratio as a predictor of 28-day mortality in critically ill pediatric patients: a retrospective cohort study.BMC pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Necrotizing enterocolitis (NEC) is a major cause of neonatal gastrointestinal morbidity and mortality. Early prediction of the need for surgical intervention remains challenging due to reliance on late clinical or radiological signs. The C-reactive protein and albumin ratio (CRP/Albumin), reflecting both inflammation and nutritional status, may serve as a dynamic biomarker to guide timely surgical decision-making. Objective The main objective of this study is to evaluate the prognostic utility of the CRP/Albumin ratio, and its temporal progression over the first three days of illness, in predicting surgical intervention and mortality in neonates. Methods In this prospective cohort study at a tertiary care hospital, Lahore, 66 neonates diagnosed with Bell's Stage I-IIIa NEC were enrolled over a year. CRP and albumin levels were measured daily for three consecutive days, and the CRP/Albumin ratio was calculated. Patients were grouped into progression trends: decreasing, increasing, stable, or variable. Outcomes included surgical intervention and mortality. Statistical analysis included receiver operating characteristic (ROC) curve analysis, sensitivity, specificity, and comparative group analysis. Results Among 66 neonates (mean gestational age: 37.2 ± 3.2 weeks), 42.4% required surgery. Neonates with an increasing CRP/Albumin ratio trend had a significantly higher rate of surgical intervention (89.5%) and mortality (26.3%) compared to those with a decreasing trend (8.1% surgery and 2.6% mortality) (p < 0.001). The CRP/Albumin ratio demonstrated excellent predictive accuracy for surgery, with area under the curve (AUC) values of 0.926, 0.954, and 0.959 on Days 1-3, respectively. Optimal cut-offs on Days 2 and 3 yielded sensitivities and specificities above 85%. Serial monitoring of the ratio outperformed single-time-point measurements in prognostic value. Conclusions CRP/Albumin is a simple, reliable, and cost-effective biomarker that can lead to early identification of neonates at risk of surgical intervention and poor outcomes in NEC. Monitoring its temporal progression, rather than relying on single measurements, appears to enhance its predictive accuracy and may support timely decision-making in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.